# Seahorse Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/seahorse-bioscience

- Industry: Biotechnology
- Headquarters: Billerica, US
- Website: www.seahorsebio.com
- Total disclosed funding: $22M
- Latest round: Series E (May 4, 2012)
- Investors on record: 9

## About

Seahorse Bioscience, Inc. specializes in advanced cell analysis technologies that empower researchers to understand cellular metabolism and health, facilitating breakthroughs in scientific research.Seahorse Bioscience, Inc. is dedicated to providing innovative solutions for cell analysis. Founded by Andrew Neilson, the company was acquired by Agilent Technologies in November 2015. Based in Billerica, Massachusetts, USA, Seahorse has successfully completed 13 deals, with its most recent funding round being Series E, raising USD 11.34 mn, which is also the total amount raised.Seahorse Bioscience delivers cutting-edge instruments for cell analysis, including the Agilent Seahorse XF platform, which provides real-time metabolic analysis. Their offerings are vital for research in cancer biology, drug discovery, and cardiovascular studies. These technologies serve a wide range of clients, including academic institutions and pharmaceutical companies across North America, Europe, and Asia-Pacific, helping address challenges in cell health and metabolism.Seahorse Bioscience generates revenue primarily from the sale of analytical instruments and software solutions, complemented by ongoing service agreements. Their business model includes direct B2B sales to research institutions and pharmaceutical firms, alongside subscription offerings for software and training services. Key products like the Agilent Seahorse XF platform contribute significantly to their revenue stream, underscoring their role in the life sciences sector.Seahorse Bioscience plans to leverage recent funding from its Series E round to enhance its product offerings and expand into new geographic markets. The company is currently working on launching advanced versions of its cell analysis technologies, targeting release dates in the upcoming quarters. There are specific plans to strengthen its presence in Europe and Asia-Pacific by 2025, aiming to increase market share and support researchers with innovative solutions that enhance experimental outcomes.

## Funding rounds

- Series E, May 4, 2012, $9.4M — Commonwealth Capital Ventures, Flagship Pioneering, EQT Life Sciences
- Series D, Feb 10, 2010, $4.8M — Commonwealth Capital Ventures, HealthCare Ventures, Oxford Bioscience Partners, Rock Maple Ventures, EQT Life Sciences, HLM Venture Partners, FLIR Systems, Inc., New Science Ventures
- Series D, Mar 9, 2009, $6M — Commonwealth Capital Ventures, Flagship Pioneering, HealthCare Ventures, Oxford Bioscience Partners, EQT Life Sciences, HLM Venture Partners, FLIR Systems, Inc., New Science Ventures
- Series B, Apr 23, 2004, $2M — Flagship Pioneering

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series B, Series D, Series E
- Commonwealth Capital Ventures (https://capitalatlas.ai/funds/commonwealth-capital-ventures) — Series D, Series E
- HealthCare Ventures — Series D
- Oxford Bioscience Partners (https://capitalatlas.ai/funds/oxford-bioscience-partners) — Series D
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series D, Series E
- HLM Venture Partners (https://capitalatlas.ai/funds/hlm-venture-partners) — Series D
- FLIR Systems, Inc. — Series D
- New Science Ventures (https://capitalatlas.ai/funds/new-science-ventures) — Series D
- Rock Maple Ventures (https://capitalatlas.ai/funds/rock-maple-ventures) — Series D